まとめ
アトリウムナトリウレチンペプチドは,アトリオペプチンIIのように,強力な冠動脈血管収縮剤として作用します. この効果には,ペプチドの二硫化物ブリッジが活性化することが必要です.
科学分野:
- 心血管生理学 心血管の生理学
- エンドクリノロジー エンドクリノロジー
- 薬理学 薬理学とは
背景:
- 心房内ナトリウレチンペプチド (ANP) は,動脈圧,心臓の充填圧,および心臓の出力を低下させることが知られている.
- 冠動脈循環におけるANPの特定の役割は完全に解明されていません.
研究 の 目的:
- 冠動脈の血流に対する特定のANPであるアトリオペプチンIIの影響を調査する.
- アトリオペプチンIIの冠動脈血管圧縮活性に対する用量反応関係と構造的要件を決定する.
主な方法:
- 孤立した,ランゲンドルフに浸透した豚,ネズミ,犬の心臓を用いて.
- 冠動脈血管収縮を評価するために,アトリオペプチンIIの様々な濃度を投与する.
- ディスルファイドブリッジの作用を減少させ,血管縮活性への影響を観察することで調査した.
主要な成果:
- アトリオペプチンIIは,ギニア豚の心臓において強力な冠動脈血管収縮活性を示し,有効用量の中位値は26ナノモールであった.
- 冠動脈の流れは,より高い用量では著しく減少し,100ナノモールでほぼ停止しました.
- ラットと犬の心臓製剤にも同様の血管圧縮効果が観察された.
- ディスルファイドブリッジの減少により,血管収縮活動が廃止されました.
結論:
- アトリオペプチンIIは,哺乳類の心臓における強力な冠動脈血管収縮剤である.
- アトリオペプチンII分子内の二硫化物ブリッジは,血管収縮機能に不可欠です.
- これらの発見は,冠動脈の血液動力学を調節するANPの複雑な役割を示唆しています.
関連する概念動画
Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...


